116 related articles for article (PubMed ID: 8738058)
21. Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis.
Hendler ED; Goffinet JA; Ross S; Longnecker RE; Bakovic V
N Engl J Med; 1974 Nov; 291(20):1046-51. PubMed ID: 4606387
[No Abstract] [Full Text] [Related]
22. Chronic, supra-physiological doses of nandrolone decanoate and exercise induced cardio-toxicity in an animal-model study.
Fineschi V
Acta Physiol (Oxf); 2013 Jun; 208(2):141-3. PubMed ID: 23480556
[No Abstract] [Full Text] [Related]
23. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial.
Johansen KL; Painter PL; Sakkas GK; Gordon P; Doyle J; Shubert T
J Am Soc Nephrol; 2006 Aug; 17(8):2307-14. PubMed ID: 16825332
[TBL] [Abstract][Full Text] [Related]
24. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis.
Sheashaa H; Abdel-Razek W; El-Husseini A; Selim A; Hassan N; Abbas T; El-Askalani H; Sobh M
Nephron Clin Pract; 2005; 99(4):c102-6. PubMed ID: 15703460
[TBL] [Abstract][Full Text] [Related]
25. A comparison of androgens for anemia in patients on hemodialysis.
Neff MS; Goldberg J; Slifkin RF; Eiser AR; Calamia V; Kaplan M; Baez A; Gupta S; Mattoo N
N Engl J Med; 1981 Apr; 304(15):871-5. PubMed ID: 7010161
[TBL] [Abstract][Full Text] [Related]
26. Response of uremic patients to nandrolone decanoate.
Doane BD; Fried W; Schwartz F
Arch Intern Med; 1975 Jul; 135(7):972-5. PubMed ID: 1156056
[TBL] [Abstract][Full Text] [Related]
27. Dose-dependent hepatic response to subchronic administration of nandrolone decanoate.
Vieira RP; França RF; Damaceno-Rodrigues NR; Dolhnikoff M; Caldini EG; Carvalho CR; Ribeiro W
Med Sci Sports Exerc; 2008 May; 40(5):842-7. PubMed ID: 18408615
[TBL] [Abstract][Full Text] [Related]
28. Nephrotoxicity in rabbits after long-term nandrolone decanoate administration.
Tsitsimpikou C; Vasilaki F; Tsarouhas K; Fragkiadaki P; Tzardi M; Goutzourelas N; Nepka C; Kalogeraki A; Heretis I; Epitropaki Z; Kouretas D; Tsatsakis AM
Toxicol Lett; 2016 Sep; 259():21-27. PubMed ID: 27346656
[TBL] [Abstract][Full Text] [Related]
29. Exuberant local tissue reaction to intramuscular injection of nandrolone decanoate (Deca-Durabolin)--a steroid compound in a sesame seed oil base--mimicking soft tissue malignant tumors: a case report and review of the literature.
Khankhanian NK; Hammers YA; Kowalski P
Mil Med; 1992 Dec; 157(12):670-4. PubMed ID: 1470383
[TBL] [Abstract][Full Text] [Related]
30. The role of nandrolone decanoate in patients with end stage renal disease in the erythropoietin era.
Johansen KL
Int J Artif Organs; 2001 Apr; 24(4):183-5. PubMed ID: 11394696
[No Abstract] [Full Text] [Related]
31. Impact of single-dose nandrolone decanoate on gonadotropins, blood lipids and HMG CoA reductase in healthy men.
Gårevik N; Börjesson A; Choong E; Ekström L; Lehtihet M
Andrologia; 2016 Jun; 48(5):595-600. PubMed ID: 26370185
[TBL] [Abstract][Full Text] [Related]
32. Chronic administration of the anabolic androgenic steroid nandrolone alters neurosteroid action at the sigma-1 receptor but not at the sigma-2 or NMDA receptors.
Elfverson M; Johansson T; Zhou Q; Le Grevès P; Nyberg F
Neuropharmacology; 2011 Dec; 61(7):1172-81. PubMed ID: 21251916
[TBL] [Abstract][Full Text] [Related]
33. Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men.
Lovejoy JC; Bray GA; Greeson CS; Klemperer M; Morris J; Partington C; Tulley R
Int J Obes Relat Metab Disord; 1995 Sep; 19(9):614-24. PubMed ID: 8574271
[TBL] [Abstract][Full Text] [Related]
34. A controlled trial of nandrolone decanoate in the treatment of rheumatoid arthritis in postmenopausal women.
Bird HA; Burkinshaw L; Pearson D; Atkinson PJ; Leatham PA; Hill J; Raven A; Wright V
Ann Rheum Dis; 1987 Mar; 46(3):237-43. PubMed ID: 3555359
[TBL] [Abstract][Full Text] [Related]
35. Reduced activity of monoamine oxidase in the rat brain following repeated nandrolone decanoate administration.
Birgner C; Kindlundh-Högberg AM; Oreland L; Alsiö J; Lindblom J; Schiöth HB; Bergström L
Brain Res; 2008 Jul; 1219():103-10. PubMed ID: 18539264
[TBL] [Abstract][Full Text] [Related]
36. Nandrolone decanoate treatment of post-menopausal osteoporosis for 2 years and effects of withdrawal.
Hassager C; Riis BJ; Pødenphant J; Christiansen C
Maturitas; 1989 Dec; 11(4):305-17. PubMed ID: 2693918
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
[TBL] [Abstract][Full Text] [Related]
38. Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.
Johnson MW; Anch AM; Remmers JE
Am Rev Respir Dis; 1984 Jun; 129(6):1023-5. PubMed ID: 6732043
[TBL] [Abstract][Full Text] [Related]
39. Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics.
Solomon LR; Hendler ED
Acta Haematol; 1988; 79(1):12-9. PubMed ID: 3124456
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
